Membrane complement regulatory proteins

Clinical Immunology

Volumn 118, Issue 2-3, 2006, Pages 127-136

  Kim, David D ^a   Song, Wen Chao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CD46; CD55; CD59; CR1; Crry; DAF; MCP; Membrane complement regulators

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; DECAY ACCELERATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE COFACTOR PROTEIN; REGULATOR PROTEIN;

AUTOIMMUNE DISEASE; CELL SURFACE; COMPLEMENT ACTIVATION; DRUG INHIBITION; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SHORT SURVEY; VASCULAR DISEASE;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; HUMANS; MEMBRANE PROTEINS;

EID: 32044432615     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2005.10.014     Document Type: Short Survey

References (121)

1. W.C. Song, M.R. Sarrias, and J.D. Lambris Complement and innate immunity Immunopharmacology 49 2000 187
2. T.E. Mollnes, W.C. Song, and J.D. Lambris Complement in inflammatory tissue damage and disease Trends Immunol. 23 2002 61
3. M.J. Walport Complement. First of two parts N. Engl. J. Med. 344 2001 1058
4. D. Hourcade, V.M. Holers, and J.P. Atkinson The regulators of complement activation (RCA) gene cluster Adv. Immunol. 45 1989 381
5. T. Miwa, and W.C. Song Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases Int. Immunopharmacol. 1 2001 445
6. D.M. Lublin, and J.P. Atkinson Decay-accelerating factor: biochemistry, molecular biology, and function Annu. Rev. Immunol. 7 1989 35
7. M.K. Liszewski, T.W. Post, and J.P. Atkinson Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster Annu. Rev. Immunol. 9 1991 431
8. J.M. Ahearn, and D.T. Fearon Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21) Adv. Immunol. 46 1989 183
9. A.P. Spicer, M.F. Seldin, and S.J. Gendler Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms J. Immunol. 155 1995 3079
10. W.C. Song, C. Deng, K. Raszmann, R. Moore, R. Newbold, J.A. McLachlan, and M. Negishi Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol- anchored form J. Immunol. 157 1996 4166
11. M.B. Powell, K.J. Marchbank, N.K. Rushmere, C.W. van den Berg, and B.P. Morgan Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59 J. Immunol. 158 1997 1692
12. Y.M. Qian, X. Qin, T. Miwa, X. Sun, J.A. Halperin, and W.C. Song Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59 J. Immunol. 165 2000 2528
13. J.L. Cole, G.A. Housley Jr., T.R. Dykman, R.P. MacDermott, and J.P. Atkinson Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines Proc. Natl. Acad. Sci. U. S. A. 82 1985 859
14. M.W. Nickells, and J.P. Atkinson Characterization of CR1- and membrane cofactor protein-like proteins of two primates J. Immunol. 144 1990 4262
15. R.W. Johnstone, B.E. Loveland, and I.F. McKenzie Identification and quantification of complement regulator CD46 on normal human tissues Immunology 79 1993 341
16. T. Miwa, M. Nonaka, N. Okada, S. Wakana, T. Shiroishi, and H. Okada Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1 Immunogenetics 48 1998 363
17. V.M. Holers, T. Kinoshita, and H. Molina The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function Immunol. Today 13 1992 231
18. B. Li, C. Sallee, M. Dehoff, S. Foley, H. Molina, and V.M. Holers Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF J. Immunol. 151 1993 4295
19. M.S. Paul, M. Aegerter, S.E. O'Brien, C.B. Kurtz, and J.H. Weis The murine complement receptor gene family. Analysis of mCRY gene products and their homology to human CR1 J. Immunol. 142 1989 582
20. W.C. Song Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury Curr. Dir. Autoimmun. 7 2004 181
21. R.M. Goodfellow, A.S. Williams, J.L. Levin, B.D. Williams, and B.P. Morgan Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis Clin. Exp. Immunol. 119 2000 210
22. M. Mizuno, K. Nishikawa, B.P. Morgan, and S. Matsuo Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59 Clin. Exp. Immunol. 119 2000 368
23. J. Hamacher, S. Sadallah, J.A. Schifferli, J. Villard, and L.P. Nicod Soluble complement receptor type 1 (CD35) in bronchoalveolar lavage of inflammatory lung diseases Eur. Respir. J. 11 1998 112
24. M.S. Mulligan, R.L. Warner, C.W. Rittershaus, L.J. Thomas, U.S. Ryan, K.E. Foreman, L.D. Crouch, G.O. Till, and P.A. Ward Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties J. Immunol. 162 1999 4952
25. H. Molina, T. Kinoshita, K. Inoue, J.C. Carel, and V.M. Holers A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2 J. Immunol. 145 1990 2974
26. T. Kinoshita, J. Takeda, K. Hong, H. Kozono, H. Sakai, and K. Inoue Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative J. Immunol. 140 1988 3066
27. V.M. Holers, and S.A. Boackle Complement receptor 2 and autoimmunity Curr. Dir. Autoimmun. 7 2004 33
28. A. Nicholson-Weller, J.P. March, S.I. Rosenfeld, and K.F. Austen Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor Proc. Natl. Acad. Sci. U. S. A. 80 1983 5066
29. M.K. Pangburn, R.D. Schreiber, and H.J. Muller-Eberhard Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria Proc. Natl. Acad. Sci. U. S. A. 80 1983 5430
30. M.K. Pangburn, R.D. Schreiber, J.S. Trombold, and H.J. Muller-Eberhard Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes J. Exp. Med. 157 1983 1971
31. W.F. Rosse, and C.J. Parker Paroxysmal nocturnal haemoglobinuria Clin. Haematol. 14 1985 105
32. C. Parker, M. Omine, S. Richards, J.I. Nishimura, M. Bessler, R. Ware, P. Hillmen, L. Luzzatto, N. Young, T. Kinoshita, W. Rosse, and G. Socie Diagnosis and management of paroxysmal nocturnal hemoglobinuria Blood 2005 3699 3709
33. T. Miyata, N. Yamada, Y. Iida, J. Nishimura, J. Takeda, T. Kitani, and T. Kinoshita Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria N. Engl. J. Med. 330 1994 249
34. M.J. Telen, and A.M. Green The Inab phenotype: characterization of the membrane protein and complement regulatory defect Blood 74 1989 437
35. D.M. Lublin, G. Mallinson, J. Poole, M.E. Reid, E.S. Thompson, B.R. Ferdman, M.J. Telen, D.J. Anstee, and M.J. Tanner Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes Blood 84 1994 1276
36. M. Yamashina, E. Ueda, T. Kinoshita, T. Takami, A. Ojima, H. Ono, H. Tanaka, N. Kondo, T. Orii, and N. Okada Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria N. Engl. J. Med. 323 1990 1184
37. T. Shichishima, Y. Saitoh, T. Terasawa, H. Noji, T. Kai, and Y. Maruyama Complement sensitivity of erythrocytes in a patient with inherited complete deficiency of CD59 or with the Inab phenotype Br. J. Haematol. 104 1999 303
38. T. Miwa, L. Zhou, B. Hilliard, H. Molina, and W.C. Song Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack Blood 99 2002 3707
39. X. Sun, C.D. Funk, C. Deng, A. Sahu, J.D. Lambris, and W.C. Song Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting Proc. Natl. Acad. Sci. U. S. A. 96 1999 628
40. D.S. Holt, M. Botto, A.E. Bygrave, S.M. Hanna, M.J. Walport, and B.P. Morgan Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria Blood 98 2001 442
41. L. Fossati-Jimack, L. Reininger, Y. Chicheportiche, R. Clynes, J.V. Ravetch, T. Honjo, and S. Izui High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia J. Exp. Med. 190 1999 1689
42. H. Molina, T. Miwa, L. Zhou, B. Hilliard, D. Mastellos, M.A. Maldonado, J.D. Lambris, and W.C. Song Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor Blood 100 2002 4544
43. M.J. Telen, S.E. Hall, A.M. Green, J.J. Moulds, and W.F. Rosse Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF J. Exp. Med. 167 1988 1993
44. M.H.J. Kraus, D.G.J. Holers, and VM A direct comparison of complement inhibitory capacities of the GPI- and transmembrane forms of mouse DAF to mouse Crry and human rsCR1 Immunopharmacology 49 2000 64
45. R.C. Riley-Vargas, D.B. Gill, C. Kemper, M.K. Liszewski, and J.P. Atkinson CD46: expanding beyond complement regulation Trends Immunol. 25 2004 496
46. M.R. Daha The possible role of membrane complement regulators in vasculitis Behring Inst. Mitt. 1993 184
47. T.M. Diaz, R. Manez, I. Moscoso, D. Lopez, I. Santamarina, E. Lopez, A. Centeno, and N. Domenech The serum level of xenoantibodies, and hDAF or alphaGAL expression on pig cells, modulate in vitro the protection given by hDAF to primate complement-mediated damage Transplant Proc. 37 2005 510
48. Z.E. Holzknecht, S. Coombes, B.A. Blocher, C.L. Lau, R.D. Davis, and J.L. Platt Identification of antigens on porcine pulmonary microvascular endothelial cells recognized by human xenoreactive natural antibodies Lab. Invest. 79 1999 763
49. S. Saadi, and J.L. Platt Immunology of xenotransplantation Life Sci. 62 1998 365
50. Y. Banz, T. Cung, E.Y. Korchagina, N.V. Bovin, A. Haeberli, and R. Rieben Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole blood Xenotransplantation 12 2005 434
51. W. Fecke, J. Long, A. Richards, and R. Harrison Protection of hDAF-transgenic porcine endothelial cells against activation by human complement: role of the membrane attack complex Xenotransplantation 9 2002 97
52. B.E. Loveland, J. Milland, P. Kyriakou, B.R. Thorley, D. Christiansen, M.B. Lanteri, M. Regensburg, M. Duffield, A.J. French, L. Williams, L. Baker, M.R. Brandon, P.X. Xing, D. Kahn, and I.F. McKenzie Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons Xenotransplantation 11 2004 171
53. S. Menoret, M. Plat, G. Blancho, F. Martinat-Botte, P. Bernard, G. Karam, L. Tesson, K. Renaudin, P. Guillouet, B. Weill, C. Chereau, L.M. Houdebine, J.P. Soulillou, M. Terqui, and I. Anegon Characterization of human CD55 and CD59 transgenic pigs and kidney xenotransplantation in the pig-to-baboon combination Transplantation 77 2004 1468
54. M. Schmoeckel, F.N. Bhatti, A. Zaidi, E. Cozzi, G. Pino-Chavez, J.J. Dunning, J. Wallwork, and D.J. White Xenotransplantation of pig organs transgenic for human DAF: an update Transplant Proc. 29 1997 3157
55. M. Schmoeckel, G. Nollert, M. Shahmohammadi, J. Muller-Hocker, V.K. Young, W. Kasper-Konig, D.J. White, C. Hammer, and B. Reichart Transgenic human decay accelerating factor makes normal pigs function as a concordant species J. Heart Lung Transplant 16 1997 758
56. W.L. Fodor, B.L. Williams, L.A. Matis, J.A. Madri, S.A. Rollins, J.W. Knight, W. Velander, and S.P. Squinto Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection Proc. Natl. Acad. Sci. U. S. A. 91 1994 11153
57. S.R. Ahmad, E.A. Lidington, R. Ohta, N. Okada, M.G. Robson, K.A. Davies, M. Leitges, C.L. Harris, D.O. Haskard, and J.C. Mason Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition Immunology 110 2003 258
58. J.C. Mason, E.A. Lidington, H. Yarwood, D.M. Lublin, and D.O. Haskard Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis Arthritis Rheum. 44 2001 138
59. J.C. Mason, H. Yarwood, K. Sugars, B.P. Morgan, K.A. Davies, and D.O. Haskard Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition Blood 94 1999 1673
60. M. Griselli, J. Herbert, W.L. Hutchinson, K.M. Taylor, M. Sohail, T. Krausz, and M.B. Pepys C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction J. Exp. Med. 190 1999 1733
61. E.T. Yeh, and J.T. Willerson Coming of age of C-reactive protein: using inflammation markers in cardiology Circulation 107 2003 370
62. S. Bhakdi, M. Torzewski, M. Klouche, and M. Hemmes Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation Arterioscler., Thromb., Vasc. Biol. 19 1999 2348
63. G.J. Wolbink, M.C. Brouwer, S. Buysmann, I.J. ten Berge, and C.E. Hack CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes J. Immunol. 157 1996 473
64. F. Niculescu, and H. Rus Complement activation and atherosclerosis Mol. Immunol. 36 1999 949
65. S.H. Li, P.E. Szmitko, R.D. Weisel, C.H. Wang, P.W. Fedak, R.K. Li, D.A. Mickle, and S. Verma C-reactive protein upregulates complement-inhibitory factors in endothelial cells Circulation 109 2004 833
66. G. Weitz-Schmidt Statins as anti-inflammatory agents Trends Pharmacol. Sci. 23 2002 482
67. J.C. Mason, Z. Ahmed, R. Mankoff, E.A. Lidington, S. Ahmad, V. Bhatia, A. Kinderlerer, A.M. Randi, and D.O. Haskard Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury Circ. Res. 91 2002 696
68. X. Qin, A. Goldfine, N. Krumrei, L. Grubissich, J. Acosta, M. Chorev, A.P. Hays, and J.A. Halperin Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes Diabetes 53 2004 2653
69. J. Acosta, J. Hettinga, R. Fluckiger, N. Krumrei, A. Goldfine, L. Angarita, and J. Halperin Molecular basis for a link between complement and the vascular complications of diabetes Proc. Natl. Acad. Sci. U. S. A. 97 2000 5450
70. C.S. Davies, C.L. Harris, and B.P. Morgan Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects Immunology 114 2005 280
71. J.W. Semple, and J. Freedman Autoimmune pathogenesis and autoimmune hemolytic anemia Semin. Hematol. 42 2005 122
72. M.J. Walport Complement. Second of two parts N. Engl. J. Med. 344 2001 1140
73. T. Miwa, M.A. Maldonado, L. Zhou, X. Sun, H.Y. Luo, D. Cai, V.P. Werth, M.P. Madaio, R.A. Eisenberg, and W.C. Song Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice Am. J. Pathol. 161 2002 1077
74. P.L. Cohen, and R.A. Eisenberg Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease Annu. Rev. Immunol. 9 1991 243
75. P.L. Cohen, and R.A. Eisenberg The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane Immunol. Today 13 1992 427
76. R.J. Mead, J.W. Neal, M.R. Griffiths, C. Linington, M. Botto, H. Lassmann, and B.P. Morgan Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis Lab. Invest. 84 2004 21
77. J. Liu, T. Miwa, B. Hilliard, Y. Chen, J.D. Lambris, A.D. Wells, and W.C. Song The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo J. Exp. Med. 201 2005 567
78. P.S. Heeger, P.N. Lalli, F. Lin, A. Valujskikh, J. Liu, N. Muqim, Y. Xu, and M.E. Medof Decay-accelerating factor modulates induction of T cell immunity J. Exp. Med. 201 2005 1523
79. G. Schrijver, M.J. Bogman, K.J. Assmann, R.M. de Waal, H.C. Robben, H. van Gasteren, and R.A. Koene Anti-GBM nephritis in the mouse: role of granulocytes in the heterologous phase Kidney Int. 38 1990 86
80. H. Sogabe, M. Nangaku, Y. Ishibashi, T. Wada, T. Fujita, X. Sun, T. Miwa, M.P. Madaio, and W.C. Song Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis J. Immunol. 167 2001 2791
81. T.V. Arumugam, I.A. Shiels, T.M. Woodruff, D.N. Granger, and S.M. Taylor The role of the complement system in ischemia-reperfusion injury Shock 21 2004 401
82. Y.H. Lien, L.W. Lai, and A.L. Silva Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice Life Sci. 74 2003 543
83. R.D. Rossen, L.H. Michael, H.K. Hawkins, K. Youker, W.J. Dreyer, R.E. Baughn, and M.L. Entman Cardiolipin-protein complexes and initiation of complement activation after coronary artery occlusion Circ. Res. 75 1994 546
84. M.L. Entman, L. Michael, R.D. Rossen, W.J. Dreyer, D.C. Anderson, A.A. Taylor, and C.W. Smith Inflammation in the course of early myocardial ischemia FASEB J. 5 1991 2529
85. C.D. Collard, M.C. Montalto, W.R. Reenstra, J.A. Buras, and G.L. Stahl Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1 Am. J. Pathol. 159 2001 1045
86. W.G. Austen Jr., L. Kobzik, M.C. Carroll, H.B. Hechtman, and F.D. Moore Jr. The role of complement and natural antibody in intestinal ischemia-reperfusion injury Int. J. Immunopathol. Pharmacol. 16 2003 1
87. R.K. Chan, S.I. Ibrahim, N. Verna, M. Carroll, F.D. Moore Jr., and H.B. Hechtman Ischaemia-reperfusion is an event triggered by immune complexes and complement Br. J. Surg. 90 2003 1470
88. S.D. Fleming, R.P. Egan, C. Chai, G. Girardi, V.M. Holers, J. Salmon, M. Monestier, and G.C. Tsokos Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice J. Immunol. 173 2004 7055
89. S.D. Fleming, T. Shea-Donohue, J.M. Guthridge, L. Kulik, T.J. Waldschmidt, M.G. Gipson, G.C. Tsokos, and V.M. Holers Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire J. Immunol. 169 2002 2126
90. K. Yamada, T. Miwa, J. Liu, M. Nangaku, and W.C. Song Critical protection from renal ischemia reperfusion injury by CD55 and CD59 J. Immunol. 172 2004 3869
91. D. Turnberg, M. Botto, M. Lewis, W. Zhou, S.H. Sacks, B.P. Morgan, M.J. Walport, and H.T. Cook CD59a deficiency exacerbates ischemia-reperfusion injury in mice Am. J. Pathol. 165 2004 825
92. A. Richards, E.J. Kemp, M.K. Liszewski, J.A. Goodship, A.K. Lampe, R. Decorte, M.H. Muslumanoglu, S. Kavukcu, G. Filler, Y. Pirson, L.S. Wen, J.P. Atkinson, and T.H. Goodship Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome Proc. Natl. Acad. Sci. U. S. A. 100 2003 12966
93. M. Noris, S. Brioschi, J. Caprioli, M. Todeschini, E. Bresin, F. Porrati, S. Gamba, and G. Remuzzi Familial haemolytic uraemic syndrome and an MCP mutation Lancet 362 2003 1542
94. I.A. Rooney, A. Davies, and B.P. Morgan Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins Immunology 75 1992 499
95. O.A. Vanderpuye, C.A. Labarrere, and J.A. McIntyre The complement system in human reproduction Am. J. Reprod Immunol. 27 1992 145
96. T.J. Oglesby, J.E. Longwith, and P.C. Huettner Human complement regulator expression by the normal female reproductive tract Anat. Rec. 246 1996 78
97. C.L. Harris, N.K. Rushmere, and B.P. Morgan Molecular and functional analysis of mouse decay accelerating factor (CD55) Biochem. J. 341 Pt. 3 1999 821
98. D.S. Holt, M.B. Powell, N.K. Rushmere, and B.P. Morgan Genomic structure and chromosome location of the gene encoding mouse CD59 Cytogenet. Cell Genet. 89 2000 264
99. L. Wang, M. Uchikawa, H. Tsuneyama, K. Tokunaga, K. Tadokoro, and T. Juji Molecular cloning and characterization of decay-accelerating factor deficiency in Cromer blood group Inab phenotype Blood 91 1998 680
100. T. Matthes, E. Tullen, J. Poole, J. Banks, M. Nagy, M.J. Stelling, F. Boehlen, M. Michel, P. Beris, H. Hustinx, V. Crew, and G. Daniels Acquired and transient RBC CD55 deficiency (Inab phenotype) and anti-IFC Transfusion 42 2002 1448
101. X. Qin, N. Krumrei, L. Grubissich, M. Dobarro, H. Aktas, G. Perez, and J.A. Halperin Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility Immunity 18 2003 217
102. S. Baalasubramanian, C.L. Harris, R.M. Donev, M. Mizuno, N. Omidvar, W.C. Song, and B.P. Morgan CD59a is the primary regulator of membrane attack complex assembly in the mouse J. Immunol. 173 2004 3684
103. K.L. Simpson, and C.H. Holmes Differential expression of complement regulatory proteins decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 during human spermatogenesis Immunology 81 1994 452
104. R.C. Riley-Vargas, S. Lanzendorf, and J.P. Atkinson Targeted and restricted complement activation on acrosome-reacted spermatozoa J. Clin. Invest. 115 2005 1241
105. M. Kurita-Taniguchi, K. Hazeki, N. Murabayashi, A. Fukui, S. Tsuji, M. Matsumoto, K. Toyoshima, and T. Seya Molecular assembly of CD46 with CD9, alpha3-beta1 integrin and protein tyrosine phosphatase SHP-1 in human macrophages through differentiation by GM-CSF Mol. Immunol. 38 2002 689
106. M. Nomura, M. Kitamura, K. Matsumiya, A. Tsujimura, A. Okuyama, M. Matsumoto, K. Toyoshima, and T. Seya Genomic analysis of idiopathic infertile patients with sperm-specific depletion of CD46 Exp. Clin. Immunogenet. 18 2001 42
107. N. Inoue, M. Ikawa, T. Nakanishi, M. Matsumoto, M. Nomura, T. Seya, and M. Okabe Disruption of mouse CD46 causes an accelerated spontaneous acrosome reaction in sperm Mol. Cell. Biol. 23 2003 2614
108. C. Xu, D. Mao, V.M. Holers, B. Palanca, A.M. Cheng, and H. Molina A critical role for murine complement regulator crry in fetomaternal tolerance Science 287 2000 498
109. D. Mao, X. Wu, C. Deppong, L.D. Friend, G. Dolecki, D.M. Nelson, and H. Molina Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway Immunity 19 2003 813
110. T. Miwa, X. Sun, R. Ohta, N. Okada, C.L. Harris, B.P. Morgan, and W.C. Song Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity Immunology 104 2001 207
111. V.M. Holers, G. Girardi, L. Mo, J.M. Guthridge, H. Molina, S.S. Pierangeli, R. Espinola, L.E. Xiaowei, D. Mao, C.G. Vialpando, and J.E. Salmon Complement C3 activation is required for antiphospholipid antibody-induced fetal loss J. Exp. Med. 195 2002 211
112. S. Rehrig, S.D. Fleming, J. Anderson, J.M. Guthridge, J. Rakstang, C.E. McQueen, V.M. Holers, G.C. Tsokos, and T. Shea-Donohue Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice J. Immunol. 167 2001 5921
113. R.J. Quigg, Y. Kozono, D. Berthiaume, A. Lim, D.J. Salant, A. Weinfeld, P. Griffin, E. Kremmer, and V.M. Holers Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor J. Immunol. 160 1998 4553
114. H.F. Weisman, T. Bartow, M.K. Leppo, H.C. Marsh Jr., G.R. Carson, M.F. Concino, M.P. Boyle, K.H. Roux, M.L. Weisfeldt, and D.T. Fearon Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis Science 249 1990 146
115. H.F. Weisman, T. Bartow, M.K. Leppo, M.P. Boyle, H.C. Marsh Jr., G.R. Carson, K.H. Roux, M.L. Weisfeldt, and D.T. Fearon Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium Trans. Assoc. Am. Physicians 103 1990 64
116. Y. Sugita, K. Ito, K. Shiozuka, H. Suzuki, H. Gushima, M. Tomita, and Y. Masuho Recombinant soluble CD59 inhibits reactive haemolysis with complement Immunology 82 1994 34
117. D.A. Fraser, C.L. Harris, A.S. Williams, M. Mizuno, S. Gallagher, R.A. Smith, and B.P. Morgan Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo J. Biol. Chem. 278 2003 48921
118. C.L. Harris, A.S. Williams, S.M. Linton, and B.P. Morgan Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo Clin. Exp. Immunol. 129 2002 198
119. H.F. Zhang, J. Yu, E. Bajwa, S.L. Morrison, and S. Tomlinson Targeting of functional antibody-CD59 fusion proteins to a cell surface J. Clin. Invest. 103 1999 55
120. C. He, M. Imai, H. Song, R.J. Quigg, and S. Tomlinson Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9 J. Immunol. 174 2005 5750
121. C. Atkinson, H. Song, B. Lu, F. Qiao, T.A. Burns, V.M. Holers, G.C. Tsokos, and S. Tomlinson Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection J. Clin. Invest. 115 2005 2444